Cytomegalovirus peptide vaccine

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCytomegalovirus peptide vaccine
Drug Alias NameCMVPepVaxCMV fusion peptide vaccines (Helocyte)CMVpp65-A*0201 peptide vaccine (Helocyte)Tet-CMV
ClassificationVaccines > Development/production technology > Synthetic peptide vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsChronic eosinophilic leukemia (CEL)Central Nervous System LymphomaLymphoproliferative Disorders +[43] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesCity Of Hope National Medical Center
Inactive CompaniesUniversity Of MinnesotaNational Cancer Institute
Active IndicationsChronic eosinophilic leukemia (CEL)Central Nervous System LymphomaLymphoproliferative Disorders +[42] 
Inactive IndicationsPrecancerous Conditions

Other Information

ATC CodeN/A
Related LinksWikipedia